(Q40532465)

21 September 2017

Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes (English)

1 reference

21 September 2017

Sheng-Hua Yang

1

1 reference

21 September 2017

Sha Li

2

1 reference

21 September 2017

Yan Zhang

3

1 reference

21 September 2017

Rui-Xia Xu

4

1 reference

21 September 2017

Yuan-Lin Guo

5

1 reference

21 September 2017

Cheng-Gang Zhu

6

1 reference

21 September 2017

Na-Qiong Wu

7

1 reference

21 September 2017

Chuan-Jue Cui

8

1 reference

21 September 2017

Jing Sun

9

1 reference

21 September 2017

Jian-Jun Li

10

1 reference

21 September 2017

17 September 2015

1 reference

Diabetes - Metabolism: Research and Reviews

21 September 2017

1 reference

21 September 2017

32

1 reference

21 September 2017

2

1 reference

21 September 2017

193-199

1 reference

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 September 2017

1 reference

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

Diabetes alters LDL receptor and PCSK9 expression in rat liver

21 January 2018

1 reference

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels

21 January 2018

1 reference

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

21 January 2018

1 reference

Genetic and metabolic determinants of plasma PCSK9 levels

21 January 2018

1 reference

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

21 January 2018

1 reference

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

21 January 2018

1 reference

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

21 January 2018

1 reference

The effect of insulin on circulating PCSK9 in postmenopausal obese women

21 January 2018

1 reference

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

21 January 2018

1 reference

HbA(1c)--an analyte of increasing importance

21 January 2018

1 reference

Haemoglobin A1c: Historical overview and current concepts

21 January 2018

1 reference

Association of glycosylated hemoglobin (HbA1c) levels with Iinsulin resistance in obese children.

21 January 2018

1 reference

Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients.

21 January 2018

1 reference

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

21 January 2018

1 reference

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

21 January 2018

1 reference

Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease

21 January 2018

1 reference

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

21 January 2018

1 reference

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

21 January 2018

1 reference

Risk of incident diabetes among patients treated with statins: population based study.

21 January 2018

1 reference

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

21 January 2018

1 reference

Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study

21 January 2018

1 reference

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes melli

21 January 2018

1 reference

Does the LDL Receptor Play a Role in the Risk of Developing Type 2 Diabetes?

21 January 2018

1 reference

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

21 January 2018

1 reference

7 January 2021

PCSK9: a convertase that coordinates LDL catabolism

1 reference

7 January 2021

Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients

1 reference

7 January 2021

Diagnosis of diabetes

1 reference

7 January 2021

Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis

1 reference

7 January 2021

Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2712

1 reference

21 September 2017

1 reference